VITROGRO
LIVE

Serial Number

79155336

Owner

Tissue Therapies Limited

Attorney

Rita E. Kline

Filing Date

Aug 28, 2014

Add to watchlist:

No watchlists yet
View on USPTO

VITROGRO Trademark

Serial Number: 79155336 • Registration: 4934476

VITROGRO is a trademark filed by Tissue Therapies Limited on August 28, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Tissue Therapies Limited (2 trademarks)

c/o Morrison & Co Level 25, Waterfront
BRISBANE 4001 , AU

Entity Type: 03

Trademark Details

Filing Date

August 28, 2014

Registration Date

April 12, 2016

Published for Opposition

January 26, 2016

Cancellation Date

October 8, 2018

Goods & Services

biological preparations, namely, spray-on skin and cultured skin grafts for burn treatment and reconstructive ophthalmic or bladder surgeries, and recombinant therapeutic proteins for medical treatment of burns, hard to heal wounds, surgically created wounds, and incisions; pharmaceutical preparations for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; veterinary preparations for horses, cattle, pigs, cats and dogs for treating burns and venous ulcers, wounds in diabetics, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; chemical preparations for cell culture for medical purposes, namely, for wound treatment; chemical reagents for medical use; biochemical reagents for medical use; recombinant proteins for medical use, namely, for use in cell culture autologous treatments, and for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological preparations for medical use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factor, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof, for the treatment of burn and venous ulcer wounds, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after surgery; biological tissue culture media for use in skin cell culture used for medical purposes; pharmaceutical preparations for skin care used for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries, and for improving the appearance of wrinkles and skin defects; medical dressings, surgical dressings, wound care components, namely, wound and surgical dressings; surgical implants, namely, arterial grafts; drugs, namely, topical creams, gels and sprays for medical purposes for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and cosmetic surgeries; drugs, namely, topical creams, gels and sprays for veterinary purposes for use on horses, cattle, pigs, cats or dogs for treating burns, venous ulcers, diabetic wounds, non-diabetic chronic wounds, surgical wounds, and to speed healing and improve recovery and scarring after ophthalmic and excisional surgeries; vaccines

chemicals for use in science and industry, namely, biological tissue cultures other than for medical or veterinary purposes; biological products for use in science and industry, namely, a 3-dimensional living skin model comprising a de-cellurized de-epidermized dermis prepared from donor skin, for in vitro and in vivo scientific and research purposes and not for medical use, namely, investigating wound healing, pharmaceutics, toxicology, drug sensitivity, drug penetration and drug delivery, and recombinant therapeutic proteins for medical treatments; biochemicals, in the nature of proteins, for in vitro and in vivo scientific or research use, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; proteins for use in the manufacture of vaccines and bio-pharmaceuticals, namely, vitronectin, fibronectin, insulin-like growth factor-I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor, fibroblast growth factors, a combination of one or more of the foregoing proteins, portions of one or more of the foregoing proteins, and chimeric proteins containing any combination of the foregoing proteins or portions thereof; kits containing biochemicals, namely, cell culture kits containing cell culture media and reagents for scientific and research use; biological products for use in science and industry, namely, biochemicals in the nature of proteins in raw form for cell culture and tissue engineering research, proteins for use in the clinical manufacture of vaccines, bio-pharmaceuticals, preparations for wound treatments, cell cultures and wound dressings; chemical reagents, namely, recombinant proteins for scientific and research use; chemicals for use in science and industry, namely, chemical preparations for cell culture for scientific and research use; chemical reagents, namely, biochemical reagents for scientific and research use and not for medical purposes; chemical reagents for scientific and research use and not for medical or veterinary purposes

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
May 3, 2019 DENC
DEATH OF INTERNATIONAL REGISTRATION
May 3, 2019 DETH
NEW REPRESENTATIVE AT IB RECEIVED
May 19, 2017 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 28, 2016 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 13, 2016 FICS
FINAL DISPOSITION PROCESSED
Jul 13, 2016 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 12, 2016 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 12, 2016 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 26, 2016 NPUB
PUBLISHED FOR OPPOSITION
Jan 26, 2016 PUBO
NOTIFICATION PROCESSED BY IB
Jan 22, 2016 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 6, 2016 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 6, 2016 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 6, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 22, 2015 PREV
ASSIGNED TO LIE
Dec 15, 2015 ALIE
EXPARTE APPEAL TERMINATED
Dec 2, 2015 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 2, 2015 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 29, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 29, 2015 CRFA
ASSIGNED TO LIE
Oct 22, 2015 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 1, 2015 ERFR
EX PARTE APPEAL-INSTITUTED
Oct 1, 2015 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Oct 1, 2015 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Oct 1, 2015 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 7, 2015 GNFN
FINAL REFUSAL E-MAILED
Apr 7, 2015 GNFR
FINAL REFUSAL WRITTEN
Apr 7, 2015 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 11, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 11, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 11, 2015 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 23, 2015 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 23, 2015 REAP
REFUSAL PROCESSED BY IB
Jan 8, 2015 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 19, 2014 RFCS
REFUSAL PROCESSED BY MPU
Dec 19, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 19, 2014 RFCR
NON-FINAL ACTION WRITTEN
Dec 18, 2014 CNRT
ASSIGNED TO EXAMINER
Dec 11, 2014 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 28, 2014 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 24, 2014 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 21, 2014 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Nov 20, 2014 SDRC